A Review on Ceftaroline in the Treatment of Community Acquired Bacterial Pneumonia

Ceftaroline fosamil (ceftaroline) is approved by the United States Food and Drug Administration (FDA) for the treatment of community-acquired pneumonia (CAP). It is a fifth-generation cephalosporin having broad-spectrum efficacy against gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP), as well as a variety of common gram-negative pathogens. Ceftaroline can bind to penicillin-binding protein (PBP)2a, an MRSA-specific PBP with minimal affinity for the majority of other β-lactam antibiotics. The drug is often given intravenously in doses of 600 mg every 12 hours for 5-7 days. Only a parenteral formulation of ceftaroline is commercially available, and the prodrug, ceftaroline fosamil, is rapidly and completely hydrolysed after intravenous administration. Ceftaroline was found to be noninferior to comparator agents in Phase II and Phase III clinical studies, with good clinical cure rates in the treatment of CAP. Ceftaroline is well tolerated, which is consistent with the cephalosporin class's safety and tolerability profile. In this review, we will evaluate the microbiological properties, pharmacological features, efficacy, safety, and tolerability of ceftaroline in the treatment of CAP.

Keywords: Ceftaroline, MRSA, CAP, efficacy.